Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:24 15/05/2024 pm IST			5-day change	1st Jan Change
44.25 ^GBX	-1.12%		-1.01%	-62.02%

07/05	AstraZeneca target raised; Antofagasta lowered	AN
01/05	Avacta picks Christina Coughlin to replace long-serving CEO	AN

Avacta picks Christina Coughlin to replace long-serving CEO

May 01, 2024 at 04:24 pm IST

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to chief executive officer from head of Research & Development. Coughlin has been an Avacta board member since March 2022 and head of R&D since this past February. She replaces Alastair Smith, who steps down on Tuesday after 19 years as CEO. Coughlin was CEO of Cytolmmune Therapeutics, which develops cell therapy solutions from a facility in Puerto Rico. She also has worked at Pfizer Inc and Novartis AG.

Current stock price: 44.40 pence

12-month change: down 63%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
NOVARTIS AG	93.3 CHF	-0.20%	+3.05%	210B
AVACTA GROUP PLC	44.25 GBX	-1.12%	-1.01%	200M
PFIZER, INC.	28.84 USD	+1.60%	+2.10%	161B

Latest news about Avacta Group Plc

AstraZeneca target raised; Antofagasta lowered	07/05	AN
Avacta picks Christina Coughlin to replace long-serving CEO	01/05	AN
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	30/04	AN
Avacta Group CEO Steps Down; Successor Appointed	30/04	MT
Transcript : Avacta Group Plc, 2023 Earnings Call, Apr 30, 2024	30/04
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	30/04	CI
Avacta Group plc Announces Chief Executive Officer Changes	30/04	CI
First Tin updates Tellerhauser estimates	22/04	AN
Transcript : Avacta Group Plc - Special Call	10/04
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	09/04	CI
Avacta doses third patient in drug conjugate trial for tumour tissue	21/03	AN
Avacta shareholders give AGM go-ahead to issue new shares	18/03	AN
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	05/03	AN
Avacta Group Upsizes Share Placement Amid Strong Investor Demand	29/02	MT
Avacta increases placing size to GBP26 million thanks to strong demand	29/02	AN
AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise	29/02	AN
Avacta plans fundraise to fund clinical development	29/02	AN
Avacta says new head of R&D Coughlin brings "deep expertise"	19/01	AN
Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer	19/01	CI
Avacta taps biopharma veteran as Therapeutics business chief	19/12	AN
Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division	19/12	CI
Avacta says study shows cancer treatment AVA6000 working as planned	13/12	AN
Transcript : Avacta Group Plc - Special Call	13/12
Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study	13/12	CI
Avacta loss widens on cost rise but clinical tests positive	28/23/28	AN

Chart Avacta Group Plc

Duration

Period

More charts

Company Profile

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Avacta Group Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4475 GBP

Average target price

0.8233 GBP

Spread / Average Target

+83.98%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AVACTA GROUP PLC	-62.02%	200M
VERTEX PHARMACEUTICALS INCORPORATED	+7.63%	111B
REGENERON PHARMACEUTICALS, INC.	+11.25%	106B
BIONTECH SE	-12.33%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.65%	16.81B
SAREPTA THERAPEUTICS, INC.	+38.63%	12.54B
LEGEND BIOTECH CORPORATION	-24.41%	8.09B

Bio Therapeutic Drugs